Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Raised 2026 ZORYVE sales guidance to $525-$540 million and received FDA approval expanding its pediatric plaque-psoriasis market. Shares closed October 19 at a period high, though the sharp rise increases pullback risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Profitability ⢠Healthy Liquidity ⢠Elevated Valuation ARQT's profitability, cash flow, and liquidity improved sharply, but elevated working capital, leverage, stock compensation, and an expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Volatile recovery ⢠Rising average ⢠Key resistance Support Level: $23.40â$23.90 Resistance Level: $26.10â$26.50 ARQT was volatile but mildly constructive last month, with support at $23.40â$23.90 and a breakout above $26.50 needed to confirm further upside.
Sentiment & News
Key News Insights: ⢠Raised guidance ⢠Zoryve momentum ⢠Institutional buying Arcutis' raised guidance, Zoryve momentum, and institutional buying support a positive outlook despite near-term earnings-estimate risk.
AI Summary
ARQT has transitioned into a profitable, cash-generating commercial biotech driven by ZORYVE's rapid growth and 92% gross margins, but its premium valuation makes sustained prescription growth, payer access, and cash conversion essential given heavy single-franchise concentration.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 19 | Oct 26 | ARQT | Arcutis Biotherapeutics, Inc. | Raised 2026 ZORYVE sales guidance to $525-$540 million and received FDA approval expanding its pediatric plaque-psoriasis market. Shares closed October 19 at a period high, though the sharp rise increases pullback risk. | Closed | -0.3% |
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |